Table 2.
A table of comparison of clinical presentations and complications observed in our study compared to studies done in other parts of India
| Vivekanandan et al.[8] | Subbalaxmi et al [9] | Sivarajan et al.[10] | Takhar et al.[11] | This study [Graphs 1–3] | |
|---|---|---|---|---|---|
| Place; sample size | Puducherry; 50 | Andhra Pradesh; 176 | Meghalaya; 90 | Rajasthan; 66 | Uttarakhand; 54 |
| Clinical features | |||||
| Fever | 50 (100%) | 176 (100%) | 75 (83.3) | 66 (100%) | 54 (100%) |
| Myalgia | 19 (38%) | NA | 56 (62.2) | 20 (30.3%) | 40 (74.07%) |
| Altered sensorium | 10 (20%) | 23 (13.1%) | 5 (19%) | 26 (39.4%) | 14 (25.92%) |
| Headache | 20 (40%) | 92 (52.3%) | 24 (26.7) | 22 (33.3%) | 45 (83.33%) |
| Cough | 20 (40%) | 94 (53.4%) | 21 (23.3) | 32 (48.5%) | 28 (51.85%) |
| Nausea/vomiting | 29 (58%) | NA | 21 (23.3) | 18 (27.3%) | 29 (53.7%) |
| Abd. pain | 10 (20%) | NA | 24 (26.7) | NA | 39 (72.22%) |
| Loose stools | 8 (16%) | 28 (15.9%) | NA | NA | 5 (9.25%) |
| Hepatosplenomegaly | 24 (48%) | 51 (28.9%) | Hepatomegaly 24 (26.7), splenomegaly 22 (24.4) | 23 (34.8%) | Hepatomegaly 10 (18%), splenomegaly 4 (7.4%) |
| Eschar | 23 (46%) | 23 (13.1%) | 10 (11.1) | 8 (12.1%) | 7 (12.96%) |
| Upper lid edema | NA | NA | NA | NA | 40 (74.07) |
| Conjunctival congestion/hemorrhage | NA | NA | NA | NA | 3 (5.55%) |
| Complications | |||||
| Leukopenia (<4000/mm3) | 1 (2%) | 42 (23.9%) | 11 (12%) | 10 (15.1%) | 1 (1.87%) |
| Leucocytosis (>11,000/mm3) | 15 (30%) | 18 (10.2%) | 23 (25%) | 20 (30.3%) | 16 (29.62%) |
| Thrombocytopenia (<100,000/mm3) | 5 (10.8%) | 53 (30.1%) | 18 (20%) | 52 (78.8%) | 7 (12.9%) |
| Raised transaminases | 47 (95.9%) | 153 (86.9%) | ALT 85 (94%), AST 90 (100%) | 32 (48.5%) | 40 (74.07%) |
| Renal failure (criteria not defined) | 6 (12%) | 49 (27.8%) | 11 (12.2%) | 34 (51.5%) | 2 (3.70%) |
| Mortality | 1 (2%) | 8 (4.5%) | 5 (5.15%) | 21.2% | 1 (1.87%) |
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NA: Data not available